About Vang-like protein 1
Vang-like protein 1 (VANGL1) is a protein
from Homo sapiens identified by UniProt accession
Q8TAA9, 524 residues long.
MolForge cross-references it against 0 known binders and
152 disease associations.
Target properties
| Protein name | Vang-like protein 1 |
| UniProt accession | Q8TAA9 |
| Gene | VANGL1 |
| Organism | Homo sapiens |
| Length | 524 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (152)
Diseases linked to this target (Open Targets).
- spina bifida · score 0.65
- familial caudal dysgenesis · score 0.50
- caudal regression sequence · score 0.40
- optic disc size measurement · score 0.38
- protein measurement · score 0.34
- ferritin measurement · score 0.30
- gut microbiome measurement · score 0.29
- leukocyte count · score 0.26
- neural tube defect · score 0.20
- genetic disorder · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TAA9-F1 | alphafold | PREDICTED | 75.60 | — |
Amino-acid sequence (524 residues)
MDTESTYSGY SYYSSHSKKS HRQGERTRER HKSPRNKDGR GSEKSVTIQP PTGEPLLGND STRTEEVQDD NWGETTTAIT GTSEHSISQE DIARISKDME DSVGLDCKRY LGLTVASFLG LLVFLTPIAF ILLPPILWRD ELEPCGTICE GLFISMAFKL LILLIGTWAL FFRKRRADMP RVFVFRALLL VLIFLFVVSY WLFYGVRILD SRDRNYQGIV QYAVSLVDAL LFIHYLAIVL LELRQLQPMF TLQVVRSTDG ESRFYSLGHL SIQRAALVVL ENYYKDFTIY NPNLLTASKF RAAKHMAGLK VYNVDGPSNN ATGQSRAMIA AAARRRDSSH NELYYEEAEH ERRVKKRKAR LVVAVEEAFI HIQRLQAEEQ QKAPGEVMDP REAAQAIFPS MARALQKYLR ITRQQNYHSM ESILQHLAFC ITNGMTPKAF LERYLSAGPT LQYDKDRWLS TQWRLVSDEA VTNGLRDGIV FVLKCLDFSL VVNVKKIPFI ILSEEFIDPK SHKFVLRLQS ETSV
Explore Vang-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets